{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:48:52Z","timestamp":1779306532579,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T00:00:00Z","timestamp":1450224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T00:00:00Z","timestamp":1450224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 074409"],"award-info":[{"award-number":["R01 074409"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 047029"],"award-info":[{"award-number":["R01 047029"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 074995"],"award-info":[{"award-number":["R01 074995"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s13365-015-0414-3","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T14:42:49Z","timestamp":1450276969000},"page":"464-471","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Predictors and characteristics of seizures in survivors of progressive multifocal leukoencephalopathy"],"prefix":"10.1007","volume":"22","author":[{"given":"Dhanashri P.","family":"Miskin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan T.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long H.","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor J.","family":"Koralnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,16]]},"reference":[{"key":"414_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/ana.24471","volume":"78","author":"T Bartsch","year":"2015","unstructured":"Bartsch T, Rempe T, Wrede A, Leypoldt F, Adams O, Rohr A, Jansen O, Bruck W, Wuthrich C, Deuschl G, Koralnik IJ (2015) Progressive hemiparesis in a psoriasis patient treated with dimethyl fumarate. Ann Neurol 78:501\u201314","journal-title":"Ann Neurol"},{"key":"414_CR2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/j.1528-1167.2009.02285.x","volume":"51","author":"E Beghi","year":"2010","unstructured":"Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW, Tomson T, Hauser WA (2010) Recommendation for a definition of acute symptomatic seizure. Epilepsia 51:671\u2013675","journal-title":"Epilepsia"},{"key":"414_CR3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","volume":"51","author":"AT Berg","year":"2010","unstructured":"Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW, Moshe SL, Nordli D, Plouin P, Scheffer IE (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005\u20132009. Epilepsia 51:676\u2013685","journal-title":"Epilepsia"},{"key":"414_CR4","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, Bartt R, Major EO, Nath A (2013) PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology 80:1430\u20131438","journal-title":"Neurology"},{"key":"414_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","volume":"10","author":"KR Carson","year":"2009","unstructured":"Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10:816\u2013824","journal-title":"Lancet Oncol"},{"key":"414_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10096-013-1941-6","volume":"33","author":"JL Casado","year":"2014","unstructured":"Casado JL, Corral I, Garcia J, Martinez-San Millan J, Navas E, Moreno A, Moreno S (2014) Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV\/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis 33:179\u2013187","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"414_CR7","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","volume":"9","author":"DB Clifford","year":"2010","unstructured":"Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9:438\u2013446","journal-title":"Lancet Neurol"},{"key":"414_CR8","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1097\/00002030-199907300-00032","volume":"13","author":"J Collazos","year":"1999","unstructured":"Collazos J, Mayo J, Martinez E, Blanco MS (1999) Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients. Aids 13:1426\u20131428","journal-title":"Aids"},{"key":"414_CR9","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1136\/jnnp-2013-304897","volume":"84","author":"S Dahlhaus","year":"2013","unstructured":"Dahlhaus S, Hoepner R, Chan A, Kleiter I, Adams O, Lukas C, Hellwig K, Gold R (2013) Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 84:1068\u20131074","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"414_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12883-015-0363-8","volume":"15","author":"N Dammeier","year":"2015","unstructured":"Dammeier N, Schubert V, Hauser TK, Bornemann A, Bischof F (2015) Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate. BMC Neurol 15:108","journal-title":"BMC Neurol"},{"issue":"Suppl 1","key":"414_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/13550280390195315","volume":"9","author":"RA Du Pasquier","year":"2003","unstructured":"Du Pasquier RA, Koralnik IJ (2003) Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 9(Suppl 1):25\u201331","journal-title":"J Neurovirol"},{"key":"414_CR12","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/epi.12550","volume":"55","author":"RS Fisher","year":"2014","unstructured":"Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshe SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S (2014) ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55:475\u2013482","journal-title":"Epilepsia"},{"key":"414_CR13","first-page":"1005","volume":"9","author":"J Gadzia","year":"2010","unstructured":"Gadzia J, Turner J (2010) Progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab. J Drugs Dermatol 9:1005\u20131009","journal-title":"J Drugs Dermatol"},{"key":"414_CR14","doi-asserted-by":"publisher","first-page":"7256","DOI":"10.1128\/JVI.02506-10","volume":"85","author":"S Gheuens","year":"2011","unstructured":"Gheuens S, Bord E, Kesari S, Simpson DM, Gandhi RT, Clifford DB, Berger JR, Ngo L, Koralnik IJ (2011) Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 85:7256\u20137263","journal-title":"J Virol"},{"key":"414_CR15","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1212\/WNL.0b013e318268465b","volume":"79","author":"S Gheuens","year":"2012","unstructured":"Gheuens S, Ngo L, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ (2012a) Metabolic profile of PML lesions in patients with and without IRIS: an observational study. Neurology 79:1041\u20131048","journal-title":"Neurology"},{"key":"414_CR16","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1212\/WNL.0b013e318253d61e","volume":"78","author":"S Gheuens","year":"2012","unstructured":"Gheuens S, Smith DR, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ (2012b) Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 78:1390\u20131393","journal-title":"Neurology"},{"issue":"Suppl 3","key":"414_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/13550280500511741","volume":"11","author":"F Gray","year":"2005","unstructured":"Gray F, Bazille C, Adle-Biassette H, Mikol J, Moulignier A, Scaravilli F (2005) Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 11(Suppl 3):16\u201322","journal-title":"J Neurovirol"},{"key":"414_CR18","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1136\/jnnp-2014-307582","volume":"85","author":"R Hoepner","year":"2014","unstructured":"Hoepner R, Ahlbrecht J, Faissner S, Schneider R, Dahlhaus S, Adams O, Raab P, Lukas C, Chan A, Stangel M, Gold R (2014) Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 85:1177\u20131178","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"414_CR19","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1136\/jnnp.74.8.1142","volume":"74","author":"C Hoffmann","year":"2003","unstructured":"Hoffmann C, Horst HA, Albrecht H, Schlote W (2003) Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry 74:1142\u20131144","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"414_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.msard.2015.05.003","volume":"4","author":"BO Khatri","year":"2015","unstructured":"Khatri BO, Garland J, Berger J, Kramer J, Sershon L, Olapo T, Sesing J, Dukic M, Rehn E (2015) The effect of dimethyl fumarate (Tecfidera) on lymphocyte counts: a potential contributor to progressive multifocal leukoencephalopathy risk. Mult Scler Relat Disord 4:377\u2013379","journal-title":"Mult Scler Relat Disord"},{"key":"414_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.24144","volume":"75","author":"MN Khoury","year":"2014","unstructured":"Khoury MN, Alsop DC, Agnihotri SP, Pfannl R, Wuthrich C, Ho ML, Hackney D, Ngo L, Anderson MP, Koralnik IJ (2014) Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathy. Ann Neurol 75:659\u2013669","journal-title":"Ann Neurol"},{"key":"414_CR22","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/archdermatol.2009.175","volume":"145","author":"BD Korman","year":"2009","unstructured":"Korman BD, Tyler KL, Korman NJ (2009) Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol 145:937\u2013942","journal-title":"Arch Dermatol"},{"key":"414_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0002-9343(98)00321-0","volume":"105","author":"N Kotecha","year":"1998","unstructured":"Kotecha N, George MJ, Smith TW, Corvi F, Litofsky NS (1998) Enhancing progressive multifocal leukoencephalopathy: an indicator of improved immune status? Am J Med 105:541\u2013543","journal-title":"Am J Med"},{"key":"414_CR24","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.jaad.2010.05.033","volume":"65","author":"N Kothary","year":"2011","unstructured":"Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M, Dal Pan G (2011) Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 65:546\u2013551","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 3","key":"414_CR25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/13550280500513325","volume":"11","author":"MA Lima","year":"2005","unstructured":"Lima MA, Koralnik IJ (2005) New features of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy and natalizumab. J Neurovirol 11(Suppl 3):52\u201357","journal-title":"J Neurovirol"},{"key":"414_CR26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1212\/01.wnl.0000194227.16696.11","volume":"66","author":"MA Lima","year":"2006","unstructured":"Lima MA, Drislane FW, Koralnik IJ (2006) Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 66:262\u2013264","journal-title":"Neurology"},{"key":"414_CR27","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1212\/01.wnl.0000423208.11698.16","volume":"79","author":"S Marousi","year":"2012","unstructured":"Marousi S, Travasarou M, Karageorgiou CE, Gheuens S, Koralnik IJ (2012) Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 79:2160, author reply 2160","journal-title":"Neurology"},{"key":"414_CR28","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1212\/01.wnl.0000242728.26433.12","volume":"67","author":"JV Martinez","year":"2006","unstructured":"Martinez JV, Mazziotti JV, Efron ED, Bonardo P, Jordan R, Sevlever G, Martinez M, Verbanaz SC, Salazar ZS, Pardal MF, Reisin R (2006) Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology 67:1692\u20131694","journal-title":"Neurology"},{"key":"414_CR29","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1097\/00002030-200109280-00028","volume":"15","author":"P Miralles","year":"2001","unstructured":"Miralles P, Berenguer J, Lacruz C, Cosin J, Lopez JC, Padilla B, Munoz L, Garcia-de-Viedma D (2001) Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. Aids 15:1900\u20131902","journal-title":"Aids"},{"key":"414_CR30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1212\/01.wnl.0000284601.54436.e4","volume":"70","author":"NM Moll","year":"2008","unstructured":"Moll NM, Rietsch AM, Ransohoff AJ, Cossoy MB, Huang D, Eichler FS, Trapp BD, Ransohoff RM (2008) Cortical demyelination in PML and MS: similarities and differences. Neurology 70:336\u2013343","journal-title":"Neurology"},{"key":"414_CR31","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1152\/jn.00742.2005","volume":"95","author":"DA Nita","year":"2006","unstructured":"Nita DA, Cisse Y, Timofeev I, Steriade M (2006) Increased propensity to seizures after chronic cortical deafferentation in vivo. J Neurophysiol 95:902\u2013913","journal-title":"J Neurophysiol"},{"key":"414_CR32","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1097\/01.inf.0000130954.41818.07","volume":"23","author":"JJ Nuttall","year":"2004","unstructured":"Nuttall JJ, Wilmshurst JM, Ndondo AP, Yeats J, Corcoran C, Hussey GD, Eley BS (2004) Progressive multifocal leukoencephalopathy after initiation of highly active antiretroviral therapy in a child with advanced human immunodeficiency virus infection: a case of immune reconstitution inflammatory syndrome. Pediatr Infect Dis J 23:683\u2013685","journal-title":"Pediatr Infect Dis J"},{"key":"414_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1742-6405-8-18","volume":"8","author":"JF Okulicz","year":"2011","unstructured":"Okulicz JF, Grandits GA, French JA, George JM, Simpson DM, Birbeck GL, Ganesan A, Weintrob AC, Crum-Cianflone N, Lalani T, Landrum ML (2011) Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study. AIDS Res Ther 8:18","journal-title":"AIDS Res Ther"},{"key":"414_CR34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s11940-013-0237-6","volume":"15","author":"O Siddiqi","year":"2013","unstructured":"Siddiqi O, Birbeck GL (2013) Safe treatment of seizures in the setting of HIV\/AIDS. Curr Treat Options Neurol 15:529\u2013543","journal-title":"Curr Treat Options Neurol"},{"key":"414_CR35","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/01.aids.0000196175.88421.eb","volume":"20","author":"MT Silva","year":"2006","unstructured":"Silva MT, Pacheco MC Jr, Vaz B (2006) Inflammatory progressive multifocal leukoencephalopathy after antiretroviral treatment. Aids 20:469\u2013471","journal-title":"Aids"},{"key":"414_CR36","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1212\/01.wnl.0000343510.08643.74","volume":"72","author":"K Tan","year":"2009","unstructured":"Tan K, Roda R, Ostrow L, McArthur J, Nath A (2009) PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 72:1458\u20131464","journal-title":"Neurology"},{"key":"414_CR37","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1212\/WNL.0b013e31822e55e7","volume":"77","author":"IL Tan","year":"2011","unstructured":"Tan IL, McArthur JC, Clifford DB, Major EO, Nath A (2011) Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77:1061\u20131067","journal-title":"Neurology"},{"key":"414_CR38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/cercor\/13.8.883","volume":"13","author":"L Topolnik","year":"2003","unstructured":"Topolnik L, Steriade M, Timofeev I (2003) Partial cortical deafferentation promotes development of paroxysmal activity. Cereb Cortex 13:883\u2013893","journal-title":"Cereb Cortex"},{"key":"414_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/NEN.0b013e31823ede59","volume":"71","author":"C Wuthrich","year":"2012","unstructured":"Wuthrich C, Koralnik IJ (2012) Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 71:54\u201365","journal-title":"J Neuropathol Exp Neurol"},{"key":"414_CR40","doi-asserted-by":"crossref","unstructured":"Xiong, W., Ping, X., Gao, J., Jin, X., 2011. Preparing undercut model of posttraumatic epileptogenesis in rodents. J Vis Exp","DOI":"10.3791\/2840"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-015-0414-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13365-015-0414-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-015-0414-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-015-0414-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T21:59:31Z","timestamp":1589666371000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13365-015-0414-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,16]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["414"],"URL":"https:\/\/doi.org\/10.1007\/s13365-015-0414-3","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,16]]},"assertion":[{"value":"26 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was supported by NIH grants R01NS 047029 and 074995.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Miskin reports no disclosures or conflicts of interest. Dr. Herman is funded by NIH grants R01 047029 and 074409; received research grants from UCB Pharma, Sage Pharmaceuticals, Acorda Therapeutics, and the Epilepsy Therapy Development Project; received consulting fees from Eisai, Inc. and Biotie, Inc. Dr. Ngo is funded by NIH grant R01 047029. Dr. Koralnik is funded by NIH grants R01 047029 and 074995; has received a research grant from Biogen Idec and the National Multiple Sclerosis Society; served on scientific advisory boards for Hoffmann La Roche, GlaxoSmithKline, Merck Serono, and MedImmune; received consulting fees from Bristol Myers Squibb, Ono Pharmaceuticals, Merck Serono, Hoffmann La Roche, GlaxoSmithKline, Perseid Therapeutics, Vertex Pharmaceuticals, and Johnson & Johnson; is an Associate Editor for the <i>Annals of Neurology<\/i>; and receives royalties from <i>UpToDate<\/i> for topics on the management of HIV and CNS mass lesions and on PML.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}